New ‘Cancer Vaccine’ for Horses in the Works (AAEP 2011)
- Topics: AAEP Convention, AAEP Convention 2011, Article, Cancer, Vaccinations
No account yet? Register
Cancer isn’t diagnosed nearly as frequently in horses as it is in humans, but approximately 80% of all white or gray horses will develop melanomas by the time they are 15 years old. Partly because of melanomas’ preferred location (near the tail, anus, groin, or salivary glands) and partly because they often aren’t diagnosed early enough, there are currently few effective treatment options, according to a veterinary internist presenting at the 2011 American Association of Equine Practitioners convention.
"One novel strategy for treating cancer in human medicine is the use of DNA vaccines that ‘target’ cancer cells," relayed Jeffrey Phillips, DVM, MS, PhD, Dipl. ACVIM, of Lincoln Memorial University’s College of Veterinary and Comparative Medicine, during the meeting, which was held Nov. 18-22 in San Antonio, Texas.
Melanocytic tumors (tumors arising from melanin-containing cells), including those diagnosed in horses, have a high level of "tyrosinase" molecules within their cells, which typically are not present in noncancerous cells. The DNA vaccine helps the immune system learn that these high levels of tyrosinase molecules are foreign, stimulating the immune system to identify and kill any cell containing elevated tyrosinase levels. In this respect the process is similar to other vaccines used in horses, such as those directed against bacteria (e.g., Streptococcus equi ) and viruses (e.g., West Nile virus), in which the immune system is stimulated to attack molecules deemed "foreign."
In a small, yet innovative, pilot study Phillips and colleagues used an FDA-approved (commercially available) canine DNA vaccine against tyrosinase in five apparently cancer-free horses (one gray and four bay in color). None of the horses experienced any adverse reactions such as painful swelling or hives, etc. All horses developed an "appropriate," detectable, and long-lasting (likely more than six months) immune response–both humoral (in the blood) and cell-mediated (; thus activating both "sides" of the immune cascade)–to the vaccine
Create a free account with TheHorse.com to view this content.
TheHorse.com is home to thousands of free articles about horse health care. In order to access some of our exclusive free content, you must be signed into TheHorse.com.
Start your free account today!
Already have an account?
and continue reading.
Related Articles
Stay on top of the most recent Horse Health news with